Australia's Biota merges with Nabi for cash and exposure to larger US investment market
This article was originally published in Scrip
Executive Summary
Australian firm Biota Holdings is to merge with Maryland-based Nabi Biopharmaceuticals and relocate to the US in a deal that is aimed at bringing Biota fresh funds, greater liquidity and a chance to move beyond its royalty-based revenue model.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.